Roshen Mathew, MD
Pulmonary Disease · Huntsville, ALNPI 1447563812
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. Noah Medical Corporation accounts for 72.8% of it on its own, with 21 other manufacturers making up the rest. Among pulmonary disease clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $158.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Noah Medical Corporation$14K
- Pulmonx Corporation$2K
- Veran Medical Technologies, Inc.$1K
- Boston Scientific$999
- Pinnacle Biologics, Inc$200
- GSK$187
- plus $952 from 16 others
What the payments were for
- Consulting fees$7,35039%
- Speaking & faculty fees$2001%
- Travel & lodging$6,17232%
- Food & beverage$2,50613%
- Education$2,80015%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Noah Medical Corporation | 24 | $13,850 |
| Pulmonx Corporation | 12 | $1,507 |
| Veran Medical Technologies, Inc. | 8 | $1,334 |
| Boston Scientific | 7 | $999 |
| Pinnacle Biologics, Inc | 1 | $200 |
| GSK | 13 | $187 |
| AstraZeneca | 10 | $136 |
| Philips North America LLC | 6 | $136 |
| Sunovion Pharmaceuticals Inc. | 9 | $114 |
| Johnson & Johnson(2 entities) | 2 | $107 |
| Genentech USA, Inc. | 5 | $93 |
| Boehringer Ingelheim | 6 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Merck | 4 | $57 |
| Mylan Specialty L.p. | 2 | $35 |
| Grifols USA, LLC | 2 | $32 |
| Shire North American Group Inc | 1 | $20 |
| Novartis | 1 | $19 |
| Intuitive Surgical | 1 | $15 |
| Insmed, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $12 |
| Electromed, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GALAXY$10,997
- Spin$1,303
- ZEPHYR ENDOBRONCHIAL VALVE$1,275
- GENERAL - THERAPIES$785
- Photofrin$200
How this compares
$19,028 in reported general payments places this provider in the 90th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 20 | $270,473 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 304 | $236,371 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $135,396 |
| Dupixent PenDupilumab | 16 | $59,873 |
| Breo ElliptaFluticasone/Vilanterol | 114 | $52,381 |
| Spiriva RespimatTiotropium Bromide | 66 | $47,664 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 72 | $45,082 |
| SymbicortBudesonide/Formoterol Fumarate | 113 | $34,280 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $25,164 |
| Advair HfaFluticasone Propion/Salmeterol | 56 | $21,372 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $20,922 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 47 | $9,352 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $9,323 |
| Spiriva HandihalerTiotropium Bromide | 16 | $9,006 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 260 | $8,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $92 | $363,218158 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $187 | $318,998481 claims |
| Grifols USA, LLCProlastin C | $32 | $135,39613 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $136 | $59,444153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Huntsville
- Luther CorleyHuntsville$86K
- Murthy VuppalaHuntsville$16K
- Richard SneeringerHuntsville$14K
- Misbahuddin SiddiquiHuntsville$12K
- Saketh Palasamudram ShekarHuntsville$11K
- Jason SmithHuntsville$8K
- William SaliskiMontgomery$257K
- Emily RehbergSylacauga$166K
- Tejaswini KulkarniBirmingham$134K
- Adrian DivittorioMobile$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.